Point72 Asset Management Reports New 5.2% Stake in Avalo Therapeutics, Inc. (AVTX)

On May 26, 2026, Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen filed a Schedule 13G disclosing a new passive ownership stake in Avalo Therapeutics, Inc. (AVTX). As of the event date on May 22, 2026, the reporting persons collectively beneficially own 2,710,817 shares of Common Stock, representing 5.2% of the company's outstanding shares. The shares are held directly by Point72 Associates, LLC, an investment fund managed by Point72 Asset Management. Point72 Capital Advisors, Inc. serves as the general partner of Point72 Asset Management, and Steven A. Cohen controls both entities. Additionally, Cubist Systematic Strategies, LLC, Point72 Asia (Singapore) Pte. Ltd., and Point72 (DIFC) Limited act as sub-advisors for portions of the reported position. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing control of the issuer. This position marks a significant increase from a previous reported holding of zero shares.